A novel inhibitor of N-ethylmaleimide-sensitive factor decreases leukocyte trafficking and peritonitis

Craig N. Morrell, Kenji Matsushita, Charles J. Lowenstein

Research output: Contribution to journalArticlepeer-review


Endothelial exocytosis is an early stage in the process of leukocyte trafficking. N-ethylmaleimide-sensitive factor (NSF) plays a critical role in regulating exocytosis. We hypothesized that inhibitors of NSF decrease endothelial exocytosis and vascular inflammation. We designed a novel fusion polypeptide consisting of a human immunodeficiency virus transactivator of transcription (TAT) protein transduction domain joined to a NSF homohexamerization domain. We show that this TAT-NSF polypeptide inhibits the ATPase activity and the disassembly activity of NSF. Furthermore, the TAT-NSF polypeptide decreases endothelial cell exocytosis and reduces leukocyte adherence to endothelial cells in culture. Finally, the TAT-NSF polypeptide inhibits leukocyte rolling on murine venules in vivo and inhibits leukocyte trafficking into the peritoneal cavity in a murine model of experimental peritonitis. These data suggest that NSF is a critical regulator of leukocyte trafficking in vivo. Novel compounds that inhibit the exocytic machinery in endothelial cells may be useful anti-inflammatory drugs.

Original languageEnglish (US)
Pages (from-to)155-161
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Issue number1
StatePublished - Jul 2005

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'A novel inhibitor of N-ethylmaleimide-sensitive factor decreases leukocyte trafficking and peritonitis'. Together they form a unique fingerprint.

Cite this